Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 6/20 | 0.58 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25175239 | 0.84 | MAPT (0.55) | POLBMAPTSIRT6ALDH1A1ADRB1 | |
| SCHEMBL25447159 | 0.84 | MAPT (0.59) | POLBMAPTSIRT6ALDH1A1ADRB1 | |
| SCHEMBL25191133 | 0.84 | POLB (0.54) | POLBMAPTSIRT6ALDH1A1ADRB1 | |
| SCHEMBL29218791 | 0.84 | MAPT (0.55) | MAPTALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL30279049 | 0.84 | MAPT (0.55) | MAPTALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL25197695 | 0.83 | POLB (0.67) | POLBMAPTSIRT6ALDH1A1ADRB1 | |
| SCHEMBL6716274 | 0.82 | MAPT (0.56) | POLBMAPTSIRT6ALDH1A1ADRB1 | |
| SCHEMBL18296386 | 0.82 | MAPT (0.59) | POLBMAPTSIRT6ALDH1A1ADRB1 | |
| SCHEMBL26641041 | 0.81 | MAPT (0.56) | POLBMAPTSIRT6ALDH1A1ADRB1 | |
| SCHEMBL15271381 | 0.79 | SIRT6 (0.81) | POLBMAPTSIRT6ALDH1A1ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115151252-B | Iron death inhibitor-diarylamine acetamides | 维泰瑞隆有限公司 | 2024-08-27 | — | — | CN | disclosed |
| US-20230159492-A1 | FERROPTOSIS INHIBITORS - DIARYLAMINE PARA-ACETAMIDES | Sironax Ltd. (KY) | 2023-05-25 | — | — | US | disclosed |
| CN-115151252-A | Iron death inhibitors diarylamine para-acetamides | 维泰瑞隆有限公司 | 2022-10-04 | — | — | CN | disclosed |
| WO-2012053606-A1 | ARYLAMINOHETEROCYCLIC CARBOXAMIDE COMPOUND | アステラス製薬株式会社 (JP) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159492-A1 | FERROPTOSIS INHIBITORS - DIARYLAMINE PARA-ACETAMIDES | AIFM2, FECH, GPX4 | POLB 4641/4885MAPT 4384/4885SIRT6 914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.